

(43) International Publication Date
17 September 2009 (17.09.2009)(10) International Publication Number
WO 2009/112461 A1

(51) International Patent Classification:

C07D 209/08 (2006.01) **C07D 239/42** (2006.01)
A61K 31/136 (2006.01) **C07D 239/48** (2006.01)
A61K 31/4418 (2006.01) **C07D 401/04** (2006.01)
A61K 31/50 (2006.01) **C07D 403/04** (2006.01)
A61K 31/505 (2006.01) **C07D 405/04** (2006.01)
C07D 213/72 (2006.01) **C07C 215/74** (2006.01)
C07D 237/20 (2006.01) **C07C 217/80** (2006.01)
C07D 239/30 (2006.01)

(21) International Application Number:

PCT/EP2009/052733

(22) International Filing Date:

9 March 2009 (09.03.2009)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

PA 2008 00371	11 March 2008 (11.03.2008)	DK
61/035,915	12 March 2008 (12.03.2008)	US

(71) Applicant (for all designated States except US): **NEUROSEARCH A/S** [DK/DK]; Pederstrupvej 93, DK-2750 Ballerup (DK).


(72) Inventors; and

(75) Inventors/Applicants (for US only): **NARDI, Antonio** [IT/DK]; c/o NeuroSearch A/S, Pederstrupvej 93, DK-2750 Ballerup (DK). **CHRISTENSEN, Jeppe, Kejsler** [DK/DK]; c/o NeuroSearch A/S, Pederstrupvej 93, DK-2750 Ballerup (DK). **PETERS, Dan** [SE/DK]; c/o NeuroSearch A/S, Pederstrupvej 93, DK-2750 Ballerup (DK).(74) Common Representative: **NEUROSEARCH A/S**; Pederstrupvej 93, DK-2750 Ballerup (DK).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG,

[Continued on next page]

(54) Title: NOVEL TRIARYL DERIVATIVES USEFUL AS MODULATORS OF NICOTINIC ACETYLCHOLINE RECEPTORS



(I)

(57) Abstract: This invention relates to novel triaryl derivatives, formula (I), a stereoisomer thereof or a mixture of its stereoisomers, or a pharmaceutically acceptable salt thereof, wherein all of X, Y and Z represent CH; or one or two of X, Y and Z represent N; and the others of X, Y and Z represent CH; and R¹, R², R³, R⁴ and R⁵, independently of each other, represent hydrogen, halo, trifluoromethyl, trifluoromethoxy, cyano, hydroxyl, alkoxy, alkyl, amino or sulfamoyl; or R¹ and R², together with the phenyl ring to which they are attached form an indolyl ring or a benzo-dioxolyl ring; and R³, R⁴ and R⁵ are as defined above; and R⁶ represents amino or nitro, which are found to be modulators of the nicotinic acetylcholine receptors. Due to their pharmacological profile the compounds of the invention may be useful for the treatment of diseases or disorders as diverse as those related to the cholinergic system of the central nervous system (CNS), the peripheral nervous system (PNS), diseases or disorders related to smooth muscle contraction, endocrine diseases or disorders, diseases or disorders related to neuro-degeneration, diseases or disorders related to inflammation, pain, and withdrawal symptoms caused by the termination of abuse of chemical substances.



SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA,
UG, US, UZ, VC, VN, ZA, ZM, ZW.

- (84) Designated States** (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))

Published:

- with international search report (Art. 21(3))
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))